수의용 API 제조 시장 규모, 점유율 및 동향 분석 보고서 : 동물 유형별, 서비스 유형별, 합성 유형별, 치료제 카테고리별, 부문별 예측(2024-2030년)

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Growth & Trends:

The global veterinary active pharmaceutical ingredients manufacturing market size is expected to reach USD 13.47 billion by 2030, registering a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The key factors driving market growth include rising animal population & pet humanization, high pet expenditure, initiatives by key market players, outsourcing of manufacturing functions to third parties, and a high prevalence of diseases in animals. Suanfarma, for instance, is involved in the veterinary manufacturing of a wide range of APIs across therapeutic categories, target species, and synthesis types. The company manufactures two proprietary APIs, namely, Tiamulin and Tetracycline HCl.

Outsourcing the manufacturing function to third parties is a significant driver of the market growth. This enables pharmaceutical companies to concentrate on their core competencies, such as R&D, regulatory affairs, and marketing. This strategic focus on core functions enhances overall operational efficiency and accelerates the development and commercialization of new veterinary APIs.Outsourcing to CMOs with expertise in animal health allows pharmaceutical companies to tap into the specialized skills of experienced professionals. This can improve product quality, compliance with regulatory standards, and enhanced manufacturing processes.Contract manufacturers with efficient processes can expedite the production timeline, allowing companies to launch their products more quickly and respond promptly to emerging market needs.

Initiatives by regulatory agencies and animal health organizations are also expected to drive market growth. For instance, in September 2023, the U.S. FDA released an agenda to promote innovation in animal biotech and veterinary products as part of the Animal and Veterinary Innovation Agenda. Thesesteps are intended to modernize the agency's approach to evaluating and supporting the development of innovative veterinary products thereby increasing regulatory efficiency, flexibility, and predictability. An increase in the number of government initiatives, that help promote animal health, is also expected to fuel the overall market growth. The launch of One Health Initiative for enhancing animal healthcare standards has improved growth prospects for the industry. This joint project unified clinical care, disease surveillance, and education & research areas for better control of diseases.

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report Highlights:

• The chemical-based API segment dominated the market with a share of 71.3% in 2023. The biological API segment is anticipated to grow at the fastest CAGR of 8.3% from 2024 to 2030
• The production animals segment held the largest revenue share in 2023. The companion animals segment is projected to grow at the fastest growth rate from 2024 to 2030
• The in-house service type segment accounted for the highest revenue share in 2023. The contract outsourcing segment is projected to grow the fastest CAGR over the forecast years
• The anti-infectives segment held the highest share in 2023. The other therapeutic category segment includes oncology, diabetes, and other drugs
• North America was the leading regional market in 2023 and held the largest revenue share of 37.8% in the same year. Asia Pacific, on the other hand, is anticipated to register the fastest CAGR of 7.9% from 2024 to 2030
• The growing need for veterinary drugs & pharmaceuticals due to the high prevalence of animal diseases and an increasing focus on pet healthcare drive the demand for veterinary APIs

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Global Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing uptake of CDMO services
    • 3.2.1.2. Increasing advancements in veterinary medicine
    • 3.2.1.3. Increasing prevalence of diseases in animals
    • 3.2.1.4. Increasing animal health expenditure
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Complex regulations
    • 3.2.2.2. Limited Awareness and Education
• 3.3. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape
• 3.4. Estimated Animal Population, by Key Species & Key Countries, 2023
• 3.5. COVID-19 Impact Analysis

Chapter 4. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: Service Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Veterinary active pharmaceutical ingredients manufacturing market: service type movement analysis, 2023 & 2030 (USD Million)
• 4.3. In House
  • 4.3.1. In house market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 4.4. Contract Outsourcing
  • 4.4.1. Contract outsourcing market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Contract Development
    • 4.4.2.1. Contract development market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2.2. Preclinical Development
    • 4.4.2.2.1. Preclinical development market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2.3. Clinical Development
    • 4.4.2.3.1. Clinical development market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Contract Manufacturing
    • 4.4.3.1. Contract manufacturing market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: Synthesis Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Veterinary active pharmaceutical ingredients manufacturing market: synthesis type movement analysis, 2023 & 2030 (USD Million)
• 5.3. Chemical-based API
  • 5.3.1. Chemical-based API market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 5.4. Biological API
  • 5.4.1. Biological API market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. HPAPI
  • 5.5.1. HPAPI market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: Animal Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Veterinary active pharmaceutical ingredients manufacturing market: animal type movement analysis, 2023 & 2030 (USD Million)
• 6.3. Production Animals
  • 6.3.1. Production animals market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 6.4. Companion Animals
  • 6.4.1. Companion animals market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: Therapeutic Category Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Veterinary active pharmaceutical ingredients manufacturing market: therapeutic category movement analysis, 2023 & 2030 (USD Million)
• 7.3. Antiparasitics
  • 7.3.1. Antiparasitics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 7.4. Anti-infectives
  • 7.4.1. Anti-infectives market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. NSAIDs
  • 7.5.1. NSAIDs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Veterinary Active Pharmaceutical Ingredients Manufacturing Market: Regional Estimates & Trend Analysis

• 8.1. Veterinary active pharmaceutical ingredients manufacturing market share, by region, 2023 & 2030, (USD Million)
• 8.2. Regional Outlook
• 8.3. North America
  • 8.3.1. North America veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. U.S. veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Canada veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. UK veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Germany veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. France veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Italy veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Spain veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Sweden veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Denmark veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Norway veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. China veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Japan
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Japan veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. India veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. South Korea veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Australia
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Australia veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Thailand veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Brazil veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Mexico
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Mexico veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. Argentina
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Argentina veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.7. Middle East and Africa
  • 8.7.1. Middle East and Africa veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Saudi Arabia veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. UAE veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.4. South Africa
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. South Africa veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Kuwait veterinary active pharmaceutical ingredients manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Position Analysis/ Heap Map Analysis
• 9.3. Company Profiles
  • 9.3.1. Zoetis
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Alivira Animal Health Limited
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Ofichem Group
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Chempro Pharma Private Limited
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Siflon Drugs
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Qilu Animal Health Products Co., Ltd.
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Vetpharma
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. SUANFARMA
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. MENADIONA
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Excel Industries Ltd.
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
• 9.4. Strategy Mapping
  • 9.4.1. Mergers & Acquisitions
  • 9.4.2. Partnerships & Collaborations
  • 9.4.3. Others
• 9.5. List of Other Key Market Players